Biotage Launches Accelerated Chromatographic Isolation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biotage Launches Accelerated Chromatographic Isolation


Biotage, a supplier of solutions and technology for analytical, medicinal and peptide chemistry, has launched a purification technology, Accelerated Chromatographic Isolation (ACI), which converts simple flash purification into a faster and more economical way to isolate pure compounds.

According to Biotage, ACI has the potential to improve chromatography efficiency in the laboratory. ACI can move users to the endpoint faster. Traditional purification takes more than 15 minutes. With ACI, the time is reduced to 5 minutes. A 250-mg scale laboratory experiment can now be purified in less than 3 minutes on a 10 g column with an ACI enabled Biotage Isolera flash purification system.

"Chemists will now have freedom to work on other things while they let their ACI system do the purification. It is fully automated, reliable and lightning fast, we can completely purify 250 mg of sample in less than 3 minutes, this is quicker than most people take to run the TLC," said Sunil Rana, global product manager, Biotage, in a press release.

Biotage Isolera systems recommend cartridges based on the sample size and programed TLC data; they work out the best solvent gradient based on compound, and provide real time indication of eluting compounds, using UV, ELSD or mass detection. They subtract signal baselines automatically so that chemists can be confident that the correct fractions are collected.

ACI works seamlessly with the Biotage Isolera system. The simple wizard quickly guides chemists through the system, beneficial for new users or those whose expertise or priorities lie in synthesis rather than purification. Existing Biotage Isolera systems can be upgraded to ACI systems. ACI will come as standard on all new production systems.

Source: Biotage

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here